Microfluidic antibody arrays for simultaneous cell separation and stimulus.

Area of Science:

• Biotechnology
• Microfluidics
• Cell Biology

Background:

• Simultaneous cell separation and drug testing is crucial for personalized medicine and cancer research.
• Existing methods often lack the efficiency and specificity required for complex cell analysis.
• Microfluidic devices offer a promising platform for high-throughput cellular assays.

Purpose of the Study:

• To develop and validate a novel microfluidic chip for simultaneous cell separation and drug testing.
• To demonstrate the chip's capability in isolating specific cell populations and evaluating drug efficacy.
• To explore its potential in analyzing antibody therapy responses against cancer cells.

Main Methods:

• Fabrication of a microfluidic chip using poly(dimethyl siloxane) (PDMS) stamping to create antibody arrays.
• Deposition of specific antibodies (e.g., anti-CD19, anti-CD71, anti-CD95) for targeted cell capture.
• Introduction of cell mixtures for separation and subsequent drug exposure within the chip.
• Analysis of cell viability and apoptosis induction using fluorescence and other readout methods.

Main Results:

• Achieved 94% capture purity for CD19+ Ramos cells using anti-CD19 antibodies.
• Demonstrated simultaneous capture of multiple cell types (e.g., B cells and T cells) using antibodies like anti-CD71.
• Showcased similar drug responses (2-10% viability) for Ramos B cells and HuT 78 T cells upon staurosporine treatment.
• Confirmed significant viability loss (15% viability) in cells captured on anti-CD95 surfaces, indicating apoptosis induction.

Conclusions:

• The developed microfluidic chip enables efficient simultaneous cell separation and drug testing.
• The device is versatile for various cell isolation and drug screening applications, including anti-cancer compound evaluation.
• This technology facilitates the study of cellular responses to therapeutic agents and antibody-based treatments.